Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Thistle

What does the research say about Thistle?

6 health outcomes synthesised

Thistle (silymarin or silibinin) has been evaluated in research for 6 health outcomes related to liver health and metabolic function. The strongest evidence, based on a moderate evidence strength from 9 studies, supports use for reducing aspartate aminotransferase (AST) levels in adults with liver conditions such as MASLD, NAFLD, and alcoholic liver disease. A common studied dose is 140 mg taken three times daily, with effects typically observed after 8 to 12 weeks.

Strongest evidence: Moderate evidence supports thistle's effects on liver enzymes. For aspartate aminotransferase (AST), 5 of 9 studies reported beneficial effects, with doses often around 140 mg three times daily. For alanine aminotransferase (ALT), 4 of 6 studies showed benefits, with two high-quality meta-analyses showing statistically significant reductions in NAFLD and drug-induced liver injury populations. All 3 studies on alkaline phosphatase (ALP) reported beneficial effects (moderate evidence), with the median study duration at about 16 weeks.

Mixed or weaker evidence: Low evidence indicates potential benefits for lipid markers. For low-density lipoprotein (LDL) and triglycerides, only 3 studies each exist, with all 3 showing small, statistically significant reductions in LDL but mixed results for triglycerides (2 beneficial out of 3). For gamma-glutamyl transferase (GGT), 2 of 3 studies showed beneficial effects, but the largest meta-analysis found a neutral effect. Conclusions in these areas remain preliminary.

Effective dose patterns: The most consistently reported dose across studies is 140 mg three times daily (total 420 mg/day) for liver enzyme improvements (AST, ALT, ALP). No specific dose or form was consistently reported for lipid outcomes (LDL, triglycerides, GGT), limiting practical application.

Population insights: Most of the research involves clinical populations with liver conditions—including nonalcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD), alcoholic liver disease (ALD), and drug-induced liver injury—with some studies in healthy adults or diabetes-related populations. Effects are typically observed after several weeks (median 59–111 days).

Notable caveats: Publication bias is a concern throughout, as null-result studies are less likely to be published. Many studies did not reach statistical significance, suggesting the true effect may be smaller than the predominant direction implies. Two small evidence bases (for ALP and LDL) rely on only 3 studies each, so conclusions are preliminary. One ALP study used a multi-ingredient product, making it hard to isolate thistle's specific effect.

Frequently asked

  • What is Thistle good for according to research?
    Research on thistle (silymarin/silibinin) primarily focuses on liver health. The strongest evidence shows it may help reduce liver enzymes, including AST (5 of 9 studies beneficial), ALT (4 of 6 studies beneficial), and ALP (3 of 3 studies beneficial). Weaker evidence suggests potential benefits for lowering LDL cholesterol and triglycerides in some clinical populations.
  • What dose of Thistle is typically used in studies?
    The most commonly reported dose in studies is 140 mg taken three times daily (420 mg per day), typically used for reducing AST and ALT levels. This dosing pattern was noted in several liver-focused trials over study durations ranging from 28 to 180 days. Many studies did not consistently report dose or form for other outcomes like LDL or triglycerides.
  • Who benefits most from Thistle?
    Research primarily involves clinical populations with liver conditions, such as adults with MASLD, NAFLD, alcoholic liver disease, acute hepatitis, or drug-induced liver injury from antituberculosis drugs. Some studies also include breast cancer patients on chemotherapy or diabetes-related populations. Effects are typically seen after several weeks of supplementation, with median study durations of 59 to 111 days depending on the outcome.
  • Are there caveats or limitations in the research on Thistle?
    Yes. Many individual trials did not reach statistical significance, so the true effect may be smaller than the overall trend suggests. Publication bias is a concern—null results are less likely to be published. Several studies lacked specific dose, form, or duration details, limiting comparability. The evidence bases for ALP, LDL, triglycerides, and GGT are small (only 3 studies each), making conclusions preliminary.
  • Does Thistle help reduce triglycerides?
    Evidence for triglyceride reduction is low and mixed. Two of 3 studies reported beneficial effects—including a 2025 systematic review of 1,221 alcoholic liver disease patients showing a large effect—but the only meta-analysis found a neutral, non-significant effect. The small evidence base (3 studies) and lack of consistent dose information mean conclusions are not robust.
  • Does Thistle help with alkaline phosphatase levels?
    Based on 3 studies, the evidence is moderately strong that thistle reduces ALP levels, with all 3 reporting statistically significant beneficial effects (small to moderate effect sizes). The populations studied include breast cancer patients on chemotherapy, patients on antituberculosis drugs, and healthy adults, with effects typically observed after about 16 weeks of use.

Safety profile

13 studies reporting safety data1 increased-risk finding1 serious adverse event

Thistle (silymarin) has been associated with an increased risk of overall adverse effects (RR 1.11–3.54) in one study, while other evidence shows no significant difference in non-serious or serious adverse events compared to placebo. Across 13 clinical studies, it was generally described as well tolerated, with mild gastrointestinal issues, insomnia, and bloating as the most commonly reported side effects. Serious adverse events were rarely reported and were not attributed to the substance.

Caveats: Most studies were short-term and designed primarily for efficacy rather than safety, so rare adverse events may not have been captured. Evidence in pregnant or lactating women and individuals with chronic conditions remains limited.

Most-studied combinations with Thistle

most supplement research is combination research
Also studied with:Turmeric (4), Resveratrol (2), Red Grape (2), Berberine (3), Vitamin E (3), Turmeric (2), green tea (2)

  • Hyperdrive 4.0

    By ALR Industries

    5 (2 reviews)
    In Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $32.15
    		In
    Vitacost
    $-
    		Out
    Vitamin Shoppe
    $-
    		Out
Back to top